IRIS
IRIS Home | Critical Effect Search Results
Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the
RfD, RfC, oral slope factor, or inhalation unit risk.
Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with
organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see
Quick Check: Assessments in Development.
Search Filtered by: Critical Effect = "Hematologic"
Number of records: 52
| Chemical Name | CASRN | Exposure Route | Critical Effect | RfD/RfC | RfD/RfC Value |
|---|---|---|---|---|---|
| Acetochlor | 34256-82-1 | Oral | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | RFD | 2 x 10 -2 mg/kg-day |
| Alachlor | 15972-60-8 | Oral | Hemosiderosis, hemolytic anemia | RFD | 1 x 10 -2 mg/kg-day |
| Amitraz | 33089-61-1 | Oral | Increased mean blood sugar concentration; slight hypothermia | RFD | 2.5 x 10 -3 mg/kg-day |
| Aniline | 62-53-3 | Inhalation | Methemoglobin increase, spleen toxicity | RFC | 1 x 10 -3 mg/m3 |
| Antimony | 7440-36-0 | Oral | Longevity, blood glucose, and cholesterol | RFD | 4 x 10 -4 mg/kg-day |
| Arsine | 7784-42-1 | Inhalation | Increased hemolysis, abnormal RBC morphology, and increased spleen weight | RFC | 5 x 10 -5 mg/m3 |
| Bayleton | 43121-43-3 | Oral | Decreased body weight gain, erythrocyte count and hemoglobin level | RFD | 3 x 10 -2 mg/kg-day |
| Benefin | 1861-40-1 | Oral | Depressed erythrocyte counts | RFD | 3 x 10 -1 mg/kg-day |
| Bentazon (Basagran) | 25057-89-0 | Oral | Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs | RFD | 3 x 10 -2 mg/kg-day |
| Bis(2-chloro-1-methylethyl) ether | 108-60-1 | Oral | Decrease in hemoglobin and possible erythrocyte destruction | RFD | 4 x 10 -2 mg/kg-day |
| Chlorimuron-ethyl | 90982-32-4 | Oral | Increase in WBC, decreased in RBC in females, increase in alkaline phosphatase in males | RFD | 2 x 10 -2 mg/kg-day |
| Chlorpropham | 101-21-3 | Oral | Kidney, spleen, liver, and bone marrow toxicity | RFD | 2 x 10 -1 mg/kg-day |
| Cyromazine | 66215-27-8 | Oral | Hematologic effects | RFD | 7.5 x 10 -3 mg/kg-day |
| 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Oral | Hematologic, hepatic and renal toxicity | RFD | 1 x 10 -2 mg/kg-day |
| Diflubenzuron | 35367-38-5 | Oral | Methemoglobin and sulfhemoglobin formation | RFD | 2 x 10 -2 mg/kg-day |
| N-N-Dimethylaniline | 121-69-7 | Oral | Splenomegaly, increased splenic hemosiderosis and hematopoiesis | RFD | 2 x 10 -3 mg/kg-day |
| 2,4-Dimethylphenol | 105-67-9 | Oral | Clinical signs (lethargy, prostration, and ataxia) and hematological changes | RFD | 2 x 10 -2 mg/kg-day |
| 2,4-Dinitrotoluene | 121-14-2 | Oral | Neurotoxicity, Heinz bodies and biliary tract hyperplasia | RFD | 2 x 10 -3 mg/kg-day |
| Diuron | 330-54-1 | Oral | Abnormal pigments in blood | RFD | 2 x 10 -3 mg/kg-day |
| 2-Ethoxyethanol | 110-80-5 | Inhalation | Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin | RFC | 2 x 10 -1 mg/m3 |
| Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Inhalation | Hemosiderin deposition in the liver | RFC | 1.6 mg/m3 |
| Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Oral | Hemosiderin deposition in the liver | RFD | 1 x 10 -1 mg/kg-day |
| Fluorene | 86-73-7 | Oral | Decreased RBC, packed cell volume and hemoglobin | RFD | 4 x 10 -2 mg/kg-day |
| Glycidaldehyde | 765-34-4 | Oral | Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects | RFD | 4 x 10 -4 mg/kg-day |
| Imazaquin | 81335-37-7 | Oral | Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK | RFD | 2.5 x 10 -1 mg/kg-day |
| Iprodione | 36734-19-7 | Oral | Increased RBC Heinz bodies; decreased prostate weight | RFD | 4 x 10 -2 mg/kg-day |
| Isopropalin | 33820-53-0 | Oral | Reduced hemoglobin concentration, lowered hematocrits, and altered organ weights | RFD | 1.5 x 10 -2 mg/kg-day |
| Linuron | 330-55-2 | Oral | Abnormal blood pigment | RFD | 2 x 10 -3 mg/kg-day |
| Mepiquat chloride | 24307-26-4 | Oral | Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects | RFD | 3 x 10 -2 mg/kg-day |
| Methyl parathion | 298-00-0 | Oral | RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs | RFD | 2.5 x 10 -4 mg/kg-day |
| Nitrate | 14797-55-8 | Oral | Early clinical signs of methemoglobinemia in excess of 10% (0-3 months old infants formula) | RFD | 1.6 mg/kg-day |
| Nitrite | 14797-65-0 | Oral | Methemoglobinemia | RFD | 1 x 10 -1 mg/kg-day |
| Nitrobenzene | 98-95-3 | Oral | Increased methemoglobin levels | RFD | 2 x 10 -3 mg/kg-day |
| Oxadiazon | 19666-30-9 | Oral | Increased levels of serum proteins and increased liver weights | RFD | 5 x 10 -3 mg/kg-day |
| Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats | RFD | 8 x 10 -4 mg/kg-day |
| Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats | RFD | 5 x 10 -3 mg/kg-day |
| Prometryn | 7287-19-6 | Oral | Liver and kidney degeneration and bone marrow atrophy | RFD | 4 x 10 -3 mg/kg-day |
| Pursuit | 81335-77-5 | Oral | Decreased packed cell volume, hemoglobin, erythrocytes in females | RFD | 2.5 x 10 -1 mg/kg-day |
| Savey | 78587-05-0 | Oral | Hypertrophy of adrenal cortex (both sexes) hematologic effects (males) | RFD | 2.5 x 10 -2 mg/kg-day |
| Selenious acid | 7783-00-8 | Oral | Clinical selenosis | RFD | 5 x 10 -3 mg/kg-day |
| Selenium and Compounds | 7782-49-2 | Oral | Clinical selenosis | RFD | 5 x 10 -3 mg/kg-day |
| Sethoxydim | 74051-80-2 | Oral | Mild anemia in males | RFD | 9 x 10 -2 mg/kg-day |
| Simazine | 122-34-9 | Oral | Reduction in weight gains hematological changes in females | RFD | 5 x 10 -3 mg/kg-day |
| Styrene | 100-42-5 | Oral | Red blood cell and liver effects | RFD | 2 x 10 -1 mg/kg-day |
| Terbutryn | 886-50-0 | Oral | Hematologic effects in females | RFD | 1 x 10 -3 mg/kg-day |
| 1,1,2-Trichloroethane | 79-00-5 | Oral | Clinical serum chemistry (effects on erythrocytes and depressed humoral immune status) | RFD | 4 x 10 -3 mg/kg-day |
| Trifluralin | 1582-09-8 | Oral | Increased liver weights; increase in methemoglobin | RFD | 7.5 x 10 -3 mg/kg-day |
| 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Decreased clotting time | RFC | 8 x 10 -2 mg/m3 |
| 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Decreased segmented neutrophils | RFC | 6 x 10 -2 mg/m3 |
| 1,3,5-Trinitrobenzene | 99-35-4 | Oral | Methemoglobinemia and spleen-erythroid cell hyperplasia | RFD | 3 x 10 -2 mg/kg-day |
| Warfarin | 81-81-2 | Oral | Increased prothrombin time | RFD | 3 x 10 -4 mg/kg-day |
| Zinc and Compounds | 7440-66-6 | Oral | Decreases in erythrocyte Cu, Zn-superoxide dismutase (ESOD) activity in healthy adult male and female volunteers | RFD | 3 x 10 -1 mg/kg-day |